-
1
-
-
84941342711
-
Preclinical evidence for the therapeutic potential of cd38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib
-
Nijhof IS, Groen RWJ, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015;21:2802-10.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2802-2810
-
-
Nijhof, I.S.1
Groen, R.W.J.2
Noort, W.A.3
Van Kessel, B.4
De Jong-Korlaar, R.5
Bakker, J.6
-
2
-
-
1642348370
-
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma
-
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121: 482-8.
-
(2004)
Am J Clin Pathol
, vol.121
, pp. 482-488
-
-
Lin, P.1
Owens, R.2
Tricot, G.3
Wilson, C.S.4
-
3
-
-
18344400217
-
Cd38: A multi-lineage cell activation molecule with a split personality
-
Malavasi F, Funaro A, Alessio M, DeMonte LB, Ausiello CM, Dianzani U, et al. CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res 1992;22:73-80.
-
(1992)
Int J Clin Lab Res
, vol.22
, pp. 73-80
-
-
Malavasi, F.1
Funaro, A.2
Alessio, M.3
DeMonte, L.B.4
Ausiello, C.M.5
Dianzani, U.6
-
4
-
-
0029909008
-
Human cd38, a cell-surface protein with multiple functions
-
Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J 1996;10:1408-17.
-
(1996)
FASEB J
, vol.10
, pp. 1408-1417
-
-
Mehta, K.1
Shahid, U.2
Malavasi, F.3
-
5
-
-
0028930578
-
Evaluation of cd38 as target for immunotherapy in multiple myeloma
-
Vooijs WC, Schuurman HJ, Bast EJ, de Gast GC. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995;85:2282-4.
-
(1995)
Blood
, vol.85
, pp. 2282-2284
-
-
Vooijs, W.C.1
Schuurman, H.J.2
Bast, E.J.3
De Gast, G.C.4
-
6
-
-
50349083286
-
Evolution and function of the adp ribosyl cyclase/cd38 gene family in physiology and pathology
-
Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008;88:841-86.
-
(2008)
Physiol Rev
, vol.88
, pp. 841-886
-
-
Malavasi, F.1
Deaglio, S.2
Funaro, A.3
Ferrero, E.4
Horenstein, A.L.5
Ortolan, E.6
-
7
-
-
0035177850
-
Human cd38: A (r)evolutionary story of enzymes and receptors
-
Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001;25:1-12.
-
(2001)
Leuk Res
, vol.25
, pp. 1-12
-
-
Deaglio, S.1
Mehta, K.2
Malavasi, F.3
-
9
-
-
84864568543
-
Proteasome inhibitors in multiple myeloma: 10 years later
-
Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
-
(2012)
Blood
, vol.120
, pp. 947-959
-
-
Moreau, P.1
Richardson, P.G.2
Cavo, M.3
Orlowski, R.Z.4
San Miguel, J.F.5
Palumbo, A.6
-
10
-
-
33745779502
-
Themolecular classification ofmultiplemyeloma
-
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. Themolecular classification ofmultiplemyeloma. Blood 2006;108:2020-8.
-
(2006)
Blood
, vol.108
, pp. 2020-2028
-
-
Zhan, F.1
Huang, Y.2
Colla, S.3
Stewart, J.P.4
Hanamura, I.5
Gupta, S.6
-
11
-
-
34547106018
-
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
-
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 585-598
-
-
Hideshima, T.1
Mitsiades, C.2
Tonon, G.3
Richardson, P.G.4
Anderson, K.C.5
-
13
-
-
84941970153
-
Daratumumab a cd38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase i/II study [abstract]
-
Dec 8-11; Atlanta GA. Washington (DC): American Society of Hematology. Abstract nr 73
-
Plesner T, Lokhorst H, Gimsing P, Nahi H, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Washington (DC): American Society of Hematology. Abstract nr 73.
-
(2012)
Proceedings of the 54th ASH Annual Meeting and Exposition
-
-
Plesner, T.1
Lokhorst, H.2
Gimsing, P.3
Nahi, H.4
Richardson, P.G.5
-
14
-
-
84939463881
-
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed refractory multiple myeloma [abstract]
-
Dec 6-9; San Francisco CA. Washington (DC): American Society of Hematology. Abstract nr 84
-
Plesner T, ArkenauH-T, Lokhorst HM, Gimsing P, Krejcik J, Lemech C, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA. Washington (DC): American Society of Hematology. Abstract nr 84.
-
(2014)
Proceedings of the 56th ASH Annual Meeting and Exposition
-
-
Plesner, T.1
Arkenau, H.-T.2
Lokhorst, H.M.3
Gimsing, P.4
Krejcik, J.5
Lemech, C.6
|